

Prof. Dr. Mehtap Tatar
Polar Sağlık Ekonomisi ve Politikası Dan. Tic. Ltd. Şti
Vitale Health Economics and Policy Ltd
mehtap.tatar@polarsaglik.com; mtatar63@gmail.com;
mehtap.tatar@vitalehealtheconomics.co.uk

Eğitim

Yıl	Üniversite	Bölüm/Bilim Alanı	Derece
1984	Hacettepe Üniversitesi	Sağlık İdaresi	Lisans
1987	Hacettepe Üniversitesi	Sağlık Kurumları Yönetim	Yüksek Lisans, M.Sc.
1988	London School of Economics and Political Science & London School of Hygiene and Tropical Medicine	Health Planning and Financing	Yüksek Lisans, M.Sc.
1993	Nottingham University	School of Social Studies, Social Policy and Administration	Doktora, Ph.D.

İş Deneyimi

Yıl	Üniversite	Pozisyon
1984-1994	Hacettepe Üniversitesi Sağlık İdaresi Y.O	Araştırma Görevlisi
1994-1996	Hacettepe Üniversitesi Sağlık İdaresi Y.O	Yardımcı Doçent
1996-2002	Hacettepe Üniversitesi Sağlık İdaresi Y.O	Doçent
2002-2006	Hacettepe Üniversitesi Sağlık İdaresi Y.O	Profesör
2006 - 2016	Hacettepe Üniversitesi İİBF Sağlık İdaresi Blm.	Profesör
2008-	Polar Sağlık Ekonomisi ve Politikası	Direktör
2020 -	Value in Health Regional Issues, CEEWAA	Editör Yardımcısı
2021-	Vitale Health Economics and Policy Ltd	Direktör

İdari Pozisyonlar

Yıl	Üniversite	Pozisyon
2002-2006	Hacettepe Üniversitesi Sağlık İdaresi YO	Müdür Yardımcısı
2006-2011	Hacettepe Üniversitesi İİBF Sağlık İdaresi Blm.	Bölüm Başkanı
2007-2011	Hacettepe Üniversitesi İİBF	Dekan Yardımcısı
2011-2016	Hacettepe Üniversitesi	Genel Sekreter V.

İİBF: İktisadi ve İdari Bilimler Fakültesi, Blm: Bölüm, YO: Yüksekokul

Projeler

1. ‘Hastanelerde Hizmet İhaleleri’, Hacettepe Üniversitesi Araştırma Fonu Proje No. 94. 04. 075. 002, 1995. *Temel Araştırmacı*
2. ‘Türkiye Ulusal Sağlık Hesapları 1999-2000’, Harvard Üniversitesi Halk Sağlığı Okulu, Uluslararası Sağlık Sistemleri Grubu ve Hacettepe Üniversitesi Sağlık İdaresi Yüksekokulu. Dünya Bankası fonları ile Sağlık Bakanlığı için yapılan proje, 2004. *Ülke Yöneticisi*
3. ‘Formal ve İnfomal Sağlık Harcamaları’, Harvard Üniversitesi Halk Sağlığı Okulu ile birlikte. Çalışma Merck, Sharp ve Dohme tarafından desteklenmiştir 2004. *Temel Araştırmacı*
4. ‘Azerbaycan Sağlık Harcamaları Çalışması’, Azerbaycan Sağlık Bakanlığı için Dünya Bankası Fonları ile yapılmıştır, 2003-2004. *Danışman*
5. ‘Azerbaycan Sağlık Finansmanı Çalışması’, Azerbaycan Sağlık Bakanlığı için Dünya Bankası Fonları ile yapılmıştır, 2004-2005. *Danışman*
6. ‘Mental Health Economics European Network Project’, London School of Economics ile Avrupa Birliği ortak projesi, 2005. *Araştırmacı*
7. ‘Health Technology Assessment Project’, European Advisory Group on Health and Social Policies, College of Europe and London School of Economics, 2005. *Araştırmacı*
8. ‘Pharmaceutical Pricing and Reimbursement Information (PPRI)’, Österreichisches Bundesinstitut für Gesundheitswesen, 2006. *Türkiye temsilcisi ve Türkiye Pharmaprofile Yazarı*
9. ‘Colorectal Cancer Project’, London School of Economics, 2007- 2008. *Araştırmacı*
10. ‘Upgrading The Statistical System & Phase II - Improvement of Hospital and Health Expenditure Statistics’, Turkey Conseil Santé contract identifier: n° L112 – R069 Service Agreement under the Framework Contract n° EuropeAid/119860/C/SV Lot n° 8 October 2007. *Danışman*
11. ‘Turkish Health Systems in Transition Profile (HIT)’, Dünya Sağlık Örgütü European Observatory, 2008. *Baş yazar*
12. ‘Pharmaceutical Health Information System (PHIS) ’, Public Health Executive Agency (PHEA), Austrian Ministry of Health, Family and Youth. *Türkiye Temsilcisi ve Türkiye PHIS raporu yazarı*
13. ‘Health Services Research Europe’, EU funded project, 2010. *Araştırmacı*
14. ‘İlaçta Geri Ödeme ve Fiyat Politikaları Konusuna Yönelik Detaylı Analiz ve Değerlendirme Çalışması’, Sağlık Bakanlığı, 2010. *Danışman*
15. ‘Diyabet Maliyeti Projesi’, London School of Economics and Political Science, Ağustos 2011. *Araştırmacı*
16. ‘Burden of Chronic Diseases in Turkey Project’, London School of Economics and Political Science, 2012. *Danışman*
17. ‘Hanehalkı Cepten Harcamalar Araştırması’, Sağlık Bakanlığı, 2013. *Danışman*

YAYINLAR

Uluslararası Dergilerde Makaleler

1. *Tatar M* (1996), "Community Participation in Health Care: The Turkish Case", *Social Science and Medicine*. 42 (11):1493-1500.
2. *Tatar M*, *Tatar F* (1997), "Primary Health Care in Turkey: Is it a Fashion or a Lasting Passion", *Health Policy and Planning*. 12 (3):224-233.
3. *Tatar M* (1997), Book Review, "Race and Community Care", *Social Science and Medicine*. 44(9): 1243.
4. *Tatar F*, *Tatar M* et al (1998), "Turkish Hospital Management at a Crossroads", *Health Administration Education Quarterly*. 16(3).
5. *Tatar M*, et. al (2000), "Women's Perception of Caesarean Section: Reflections from a Turkish Teaching Hospital", *Social Science and Medicine*. 50: 1227-1233.
6. *Tatar M*, *Erigüç G* (2000), "Turkish Health Care Reforms and Reasons for Failure", *Tavakoli, M., Davies H.T.O., Malek, M. (eds) Health Policy and Economics: Strategic Issues in Health Care Management Ashgate Publishing Ltd*.
7. *Ağırbaş İ*, *Tatar M* (2005), "Benign prostatic hyperplasia: cost and effectiveness of three alternative surgical treatment methods used in a Turkish hospital", *Journal of Medical Systems*, 29(5):487-492.
8. *Şahin B*, *Tatar M* (2006), "Analysis of Factors Affecting Patient Satisfaction: A Case Study with Asthma Patients", *Journal of Disease Management and Health Outcomes*. 14(3).
9. *Tatar M*, *Kanavos P* (2006), "Health Care Reform in Turkey: A Dynamic Path in the Wake of Political Consensus", *Eurohealth*. 12(1).
10. *Şahin B*, *Tatar M* (2006), "Factors Affecting Use of Resources for Asthma Patients", *Journal of Medical Systems*. 30:395-403.
11. *Tatar M*, *Özgen H*, *Şahin B*, *Belli P*, *Berman P* (2007), "Informal Payments in the Health Sector: A Case Study from Turkey", *Health Affairs*. 26(4).
12. *Akbulut Y*, *Tatar M*, *Çetinyürek A*, *Tatar F* (2008), "Non-urgent use of the emergency department: A quantitative evaluation from a patient perspective", *Journal of Management and Marketing in Health Care*. 1(4).
13. *Özgen H*, *Şahin B*, *Belli P*, *Tatar M*, *Berman P* (2009), "Predictors of Informal Health Payments: The Example from Turkey", *Journal of Medical Systems*. 34(3):387-96.
14. *Akbulut Y*, *Tatar M*, *Demir A* (2005), "Standardized Mortality Ratios and Allocation of Health Care Resources: Turkey Case", in *Yfantopoulos, J.N., (ed) The Economics of Health Care Reforms*, Athens Institute for Education and Research, Athens.
15. *Tatar M*, *Tatar F* (2009), "Colorectal Cancer in Turkey: Current Situation- and Challenges for the future", *European Journal of Health Economics*.10 DOI 10.1007/s10198-009-0197-7.
16. *Somunoğlu S*, *Tatar, M* (2009), "The Use of Screening for Early Diagnosis of Breast Cancer in Ankara", *Social Behavior and Personality*. 37(8):1101-1110.
17. *Somunoğlu S*, *Tatar, M.* (2012),"A study on the identification of factors affecting the life quality of breast cancer patients", *International Journal of Pharmaceutical and Healthcare Marketing*. 6(4): 376 – 396.
18. *Tatar M*, *Ergin G*, *Eceder T* (2013), 'Cost Analysis of Private Hemodialysis Centers in Turkey', *Turkish Nephrology*. 22(03):270-282. DOI:10.5262/tndt.2013.1003.07
19. *Tatar M*, (2013) 'Management of diabetes and diabetes policies in Turkey', *Globalization and Health*. 9(16). Doi: 10.1186/1744-8603-9-16.

20. Lichtenberg F, *Tatar M*, Çalışkan Z (2014), 'The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010', *Health Policy*, 117(3): 361-373.
21. Koçkaya G, Yenilmez FB, Ergin G, Atikeler K, *Tatar M* (2013), 'Operational Cost of Obesity Surgery in Turkey', *Eur J Endosc Laparosc Surg*. 1(2):78-83.
22. Turgay S, Aksu K, Dokuyucu O, Ertenli A, Gül A, Karaaslan Y, Kasapcopur O, Kiraz S, Onat OM, Ozdogan H, Ozen S, Saylan M, Senturk A, Sevgi S, Cavusoglu SS, *Tatar M*, Tuna E, Turanlı M, Yalcinkaya F (2015), 'Epidemiology of colchicine resistant Familial Mediterranean Fever disease (CrFMF) in Turkey', *Pediatric Rheumatology*. 13(Suppl 1):P90. DOI:10.1186/1546-0096-13-S1-P90
23. Koçkaya G, Demir M, Koçkaya PD, *Tatar M*, Üresin Y (2015), 'Economic Impact of Clinical Research to Research Centers and Opportunity Cost for the Reimbursement System in Turkey', *Health*. 07(09):1124-1133. DOI:10.4236/health.2015.79128
24. *Tatar M*, et al (2016), 'Cost of treatment of chronic spontaneous urticaria in Turkey', *Health*. 8, 1098-1103.
25. Lichtenberg F, *Tatar M*, Çalışkan Z (2017), 'The Impact of Innovation on Health Outcomes and Utilization in Turkey: a Re-Examination', *Health Policy and Technology*. 6(2): 226-2333. DOI: <http://dx.doi.org/10.1016/j.hlpt.2017.01.003>
26. Tuncer MA, *Tatar M*, Şahin İ (2017), 'University Hospitals in Turkey: Structural Crisis in Financing or Consequences of Mismanagement', *Journal of Hospital Administration*. 6(4): 52-60.
27. *Tatar M*, Alkış N, Güçlü ÇY, Bermede O, Erdemli B, Günaydın S (2022), 'Cost-Effectiveness and Budget Impact of Comprehensive Anemia Management, The First Pillar of Patient Blood Management, on the Turkish Healthcare System', *ClinicoEconomics and Outcomes Research*. 14: 415-426.
28. Şanal L, Günaydın S, *Tatar M* (2023), 'Cost-Effectiveness and Budget Impact Analyses of Patient Blood Management in a Cardiovascular Surgery Department at Ankara Bilkent City Hospital in Turkey', *Adv Ther*. <https://doi.org/10.1007/s12325-023-02733-5>
29. Dane F, *Tatar M* et al (2024), 'Cost of Hepatocellular Carcinoma from the Payer's Perspective in Türkiye: Results of a Delphi Panel Analysis', *Global Journal of Medical and Pharmaceutical Sciences*. 3(9): 13-24. <https://doi.org/10.55640/gimps/Volume03Issue09-03>

Uluslararası Posterler

1. Şahin B, *Tatar M*, Karakaya G, Kalyoncu F (2003), 'The validity and the reliability of the Turkish version of asthma quality of life questionnaire', *European Respiratory Society Annual Congress*, Vienna.
2. Şahin B, Demir C, *Tatar M* (2004), 'The importance of measurement of case mix and severity of illness in evaluation of hospital and physician performance', *Congress of başkan Miliary Medical Committee*, Antalya.
3. *Tatar M*, Özgen H, Şahin B, Belli P, Berman P (2005), 'Formal and informal payments for health in Turkey', *International Health Economics Association 5th World Congress*, Barcelona.
4. *Tatar M*, Akbulut H (2009), 'Cost effectiveness of Sorafenib in unresectable and/or metastatic renal cell carcinoma in Turkey', *Value in Health*. 12(7): A 222. [https://www.valueinhealthjournal.com/article/S1098-3015\(10\)74082-1/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(10)74082-1/pdf)

5. *Tatar M, Sariöz F* (2010) ‘Cost efficacy of Ustekinumab in treatment of moderate to severe plaque psoriasis in Turkey’, *Value in Health*. 13(3). [https://www.valueinhealthjournal.com/article/S1098-3015\(10\)72711-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(10)72711-X/pdf)
6. *Tatar M, Sariöz F* (2010), ‘Cost efficacy of ustekinumab in treatment of moderate to severe plaque psoriasis in Turkey’, ISPOR 15th Annual International Meeting Atlanta.
7. *Tatar M* (2011), ‘World Perspective: Turkey’, PPRI Conference, Vienna.
8. *Tatar M, Ergin G, Koçkaya G* (2012), ‘Cost analysis of dialysis practice in Turkey’, *Value in Health*. 15(7): A523-A524. [https://www.valueinhealthjournal.com/article/S1098-3015\(12\)03519-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(12)03519-X/pdf)
9. *Tatar M, Dilbaz N, Oral ET, Tan M,* (2012), ‘Cost effectiveness of Agomelatine in treatment of major depressive disorders in Turkey’, *Value in Health*. 15(4). [https://www.valueinhealthjournal.com/article/S1098-3015\(12\)00545-1/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(12)00545-1/pdf)
10. *Kockaya G, Tatar M, Ergin G, Atikeler K* (2013) ‘Cost of Obesity and Economic Value of Obesity Surgery for Turkey (CEVOS-T)’, *Value in Health*. 16(7):A381. DOI:10.1016/j.jval.2013.08.340 [https://www.valueinhealthjournal.com/article/S1098-3015\(13\)02245-6/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(13)02245-6/pdf)
11. *Tatar M, et al* (2013), ‘Cost of obesity for Turkey’, 18th World Congress of International Federation for Surgery of Obesity and Metabolic Disorders, İstanbul.
12. *Koçkaya G, Atikeler K, Ergin G, Tatar M, et al* (2013), ‘Economic value of obesity surgery for Turkey’, 18th World Congress of International Federation for Surgery and Obesity and Metabolic Disorders, İstanbul.
13. *Ergin G, Koçkaya G, Atikeler K, Tatar M, et al* (2013), ‘Operational cost of obesity surgery for Turkey’, 18th World Congress of International Federation for Surgery and Obesity and Metabolic Disorders, İstanbul.
14. *Tuna E, Tatar M, Ergin G, Senturk A, Atikeler K* (2014), ‘Availability of Risk Sharing Agreements in the Turkish Pharmaceutical Sector’, *Value in Health*. 17(7):A415. DOI:10.1016/j.jval.2014.08.1000 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02930-1/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02930-1/pdf)
15. *Tuna E, Tatar M, Ergin G, Senturk A, Atikeler K* (2014), ‘Development of HTA in Turkey’, *Value in Health*, 17(7):A445. DOI:10.1016/j.jval.2014.08.1180 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)03110-6/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)03110-6/pdf)
16. *Yenilmez FB, Kockaya G, Saylan M, Safak YE, Tatar M, Vural E, Hilal IM, Vural A, Akbulat H, Gursoz G, Artıran S, Kerman S* (2014), ‘Impact of Health Policy Changes on the Cost Sales of 5 Top Selling ATC1 Pharmaceutical Groups in Turkey’, *Value in Health*. 17(7):A410. [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02894-0/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02894-0/pdf) DOI:10.1016/j.jval.2014.08.964
17. *Safak, YE, Kockaya G, Yenilmez FB, Saylan M, Tatar M, Hilal VE, Vural IM, Akbulat A, Gursoz H, Artıran G, Kerman S* (2014), ‘Impact of Health Policy Changes on Trends of Pharmaceutical Market in Turkey’, *Value in Health*. 17(7):A408. DOI:10.1016/j.jval.2014.08.957 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02887-3/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02887-3/pdf)
18. *Saylan M, Safak YE, Yenilmez FB, Kockaya G, Tatar M, Hilal VE, Vural IM, Akbulat A, Gursoz H, Artıran G, Kerman S* (2014), ‘Impact Of Health Policy Changes on Unit Sales of 5 Top Selling ATC1 Phramaceutical Groups In Turkey’, *Value in Health*.

- 17(7):A411. DOI:10.1016/j.jval.2014.08.972
[https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02902-7/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02902-7/pdf)
19. Hilal VE, Koçkaya G, Yenilmez FB, Saylan M, Safak YE, *Tatar M*, Vural IM, Akbulat A, Gursoz H, Artiran G, Kerman,S (2014), ‘ Impact of Health Policy Changes on the Growth Locally Manufactured and Imported Pharmaceutical Markets In Turkey’, *Value in Health*. 17(7):A410. DOI:10.1016/j.jval.2014.08.967
[https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02897-6/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02897-6/pdf)
20. Atikeler K, Tuna E, Yenilmez FB, *Tatar M*, Kockaya G (2014), ‘Value of Life And Cost of Pre-Mature Deaths With The Perspective Of Productivity As Net Tax Revenue: A Comparison In Argentina, Brazil And Mexico’, *Value in Health*. 17(7):A425. DOI:10.1016/j.jval.2014.08.1059 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02989-1/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02989-1/pdf)
21. *Tatar M*, Senturk A, Dalgali Y (2014), ‘Cost-Effectiveness of Use of Barricaid® In Lumbar Discectomy Surgery in Turkey’, *Value in Health*. 17(7):A380. DOI:10.1016/j.jval.2014.08.2614 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)04563-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)04563-X/pdf)
22. *Tatar M*, Sezen S, Senturk A, Balp MM, Saylan M, Keskinaslan A (2014), ‘Cost-Effectiveness of Omalizumab in Chronic Idiopathic Urticaria Refractory to H1-Antihistamines in Turkey’, *Value in Health*. 17(7):A604. DOI:10.1016/j.jval.2014.08.2101 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)04031-5/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)04031-5/pdf)
23. Kockaya G, Yenilmez FB, Saylan M, Safak YE, *Tatar M*, Hilal VE, Vural IM, Akbulat A, Gursoz H, Artiran G, Kerman S (2014), ‘Impact of Health Policy Changes on the Growth Locally Manufactured and Imported Pharmaceutical Markets of Top Selling Atc1 Phramaceutical Group (Alimentary and Metabolism (A0) In Turkey’, *Value in Health*. 17(7):A410-A411. DOI:10.1016/j.jval.201.; 4.08.969
[https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02899-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02899-X/pdf)
24. *Tatar M*, Senturk A, Ergin G, Tuna E, Mat C, Baskan E, Bulbul F, Artuz MA, Gurer N, Atakan S, Inaloz S, Sezen A, Keskinaslan A, Saylan M (2014), ‘Cost-Analysis of Chronic Idiopathic Urticaria Disease’, *Value in Health*. 17(7):A606. DOI:10.1016/j.jval.2014.08.2114 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)04044-3/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)04044-3/pdf)
25. Yenilmez FB, Tuna E, Atikeler K, Kockaya G, *Tatar M* (2014), ‘Value of Life And Cost of Pre-Mature Deaths With The Perspective Of Productivity As Net Tax Revenue: A Comparison In Usa, Canada, Japan and Australia’, *Value in Health*. 17(7):A423. DOI:10.1016/j.jval.2014.08.1050 [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02980-5/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02980-5/pdf)
26. Tuna E, Yenilmez FB, Atikeler K, Kockaya G, *Tatar M* (2014), ‘Value of Life and Cost of Pre-Mature Deaths With The Perspective of Productivity As Net Tax Revenue: A Comparison in France, Germany, Italy, Spain, United Kingdom’, *Value in Health*. 17(7):A424. DOI:10.1016/j.jval.2014.08.1054
[https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02984-2/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02984-2/pdf)
27. Kockaya G, Tuna E, Yenilmez FB, Atikeler K, *Tatar M* (2014), ‘Value of Life And Cost of Pre-Mature Deaths With the Perspective of Productivity As Net Tax Revenue for Turkey’,

- Value in Health. 17(7):A424-A425. DOI:10.1016/j.jval.2014.08.1057
[https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02987-8/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(14)02987-8/pdf)
28. Tatar M, Tuna E, Caglayan B, Sarica N, Firidin A (2015), ‘*Cost Effectiveness of Sodium Oxybate In Treatment of Cataplexy In Patients With Narcolepsy In Turkey*’, Value in Health. 18(7):A757. DOI:10.1016/j.jval.2015.09.2465
[https://www.valueinhealthjournal.com/article/S1098-3015\(15\)04541-6/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)04541-6/pdf)
 29. Tatar M, Senturk A, Tuna E, Karabulut E, Caliskan Z, Arsava ME, Topcuoglu MA (2015), ‘*Direct Treatment Costs Of Stroke In Turkey*’, Value in Health, 18(7):A388. DOI:10.1016/j.jval.2015.09.855 [https://www.valueinhealthjournal.com/article/S1098-3015\(15\)02931-9/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)02931-9/pdf)
 30. Dogan E, Kockaya G, Tuna E, Yenilmez FB, Vural IM, Akbulat A, Artrran G, Tatar M, Unal O (2015), ‘*General Assessment Of Unlicensed Medicine Usage In Turkey*’, Value in Health. 18(7):A532. DOI:10.1016/j.jval.2015.09.1660
[https://www.valueinhealthjournal.com/article/S1098-3015\(15\)03736-5/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)03736-5/pdf)
 31. Yenilmez FB, Kockaya G, Dogan E, Tuna E, Vural IM, Akbulat A, Artrran G, Tatar M, Unal O (2015), ‘*General Assessment Of Unlicensed Antineoplastic And Immunomodulating Medicine Usage Subgroups In Turkey*’, Value in Health. 18(7):A537. DOI:10.1016/j.jval.2015.09.1688 [https://www.valueinhealthjournal.com/article/S1098-3015\(15\)03764-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)03764-X/pdf)
 32. Tatar M, Senturk A, Tuna E, Bilginer B, Ulus AT, Buyuktuna,N, Hacibedel B, Saribaş G, (2015), ‘*Local Cost Study Of Treatment Of Venous Thromboembolism In Turkey*’, Value in Health. 18(7):A388-A389. DOI:10.1016/j.jval.2015.09.856
[https://www.valueinhealthjournal.com/article/S1098-3015\(15\)02932-0/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)02932-0/pdf)
 33. Caglayan B, Firidin A, Yildirim N, Tatar, M, Essiz M (2015), ‘*Cost-Effectiveness of Certolizumab Pegol for The Treatment of Axial Spondyloarthritis In Turkey*’, Value in Health. 18(7):A645. DOI:10.1016/j.jval.2015.09.2309
[https://www.valueinhealthjournal.com/article/S1098-3015\(15\)04385-5/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)04385-5/pdf)
 34. Aksu K, Dokuyucu Ö, Ertenli Aİ, Gul A, Karaaslan Y, Kasapcopur O, Kiraz, S. Onat AM, Ozdogan AH, Ozbalas T, Ozen S, Saylan M, Senturk A, Tatar M, Tuna E, Turanlı M, Yalcinkaya F (2015), ‘*Cost of Familial Mediterranean Fever (Fmf) Disease In Turkey*’, Value in Health. 18(7):A666. DOI:10.1016/j.jval.2015.09.2427
[https://www.valueinhealthjournal.com/article/S1098-3015\(15\)04503-9/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)04503-9/pdf)
 35. Tuna E, Kockaya G, Yenilmez FB, Dogan E, Vural IM, Akbulat A, Artrran G, Tatar, M, Unal O, (2015), ‘*General Assessment Of Unlicensed Antineoplastic And Immunomodulating Medicine Usage In Turkey*’, Value in Health. 18(7):A529-A530. DOI:10.1016/j.jval.2015.09.1644 [https://www.valueinhealthjournal.com/article/S1098-3015\(15\)03720-1/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)03720-1/pdf)
 36. Tatar M, Tuna E, Senturk A, Alanoğlu Z, Aypar U, Değirmenci S, Ulus P (2016), ‘*Comparison of Sugammadex and Neostigmine Use in Terms of Cost Savings in Hospitals in Turkish Health Care Setting*’, Value in Health. 19: A 245.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)01117-7/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)01117-7/pdf)
 37. Tatar M, Tuna E, Oguzhan G, Senturk A, Sozeri B, Ayaz N, Turgay S, Turanlı M, Makay B, Demirkaya E, Unsal E, Kasapcopur O, Ozen S (2015), ‘*How Pricing And Reimbursement Policies Affect The Budget Impact of The Treatment of Systemic Juvenile*

Idiopathic Arthritis In Turkey', Value in Health. 18(7):A643.

DOI:10.1016/j.jval.2015.09.2300 [https://www.valueinhealthjournal.com/article/S1098-3015\(15\)04376-4/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)04376-4/pdf)

38. *Tatar M, Senturk A, Tuna E, Darrigol S, Girard L, Kayin J* (2015), 'Cost Saving Study Of Five Grass Pollen Slit Tablet Versus Scit's & Symptomatic Treatment', Value in Health. 18(7):A497. DOI:10.1016/j.jval.2015.09.1397
[https://www.valueinhealthjournal.com/article/S1098-3015\(15\)03473-7/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(15)03473-7/pdf)
39. *Altundag K, Basaran G, Oksuzoglu B, Oven B, Ozguroglu M, Aydin D, Hacibedel,B, Helvacioğlu K, Tuna E, Tatar M* (2016), 'Treatment Algorithm and Direct Costs of Treatment of HR+/HER2- Post Menopausal Advanced/Metastatic Breast Cancer Patients in Turkey', Value in Health. 19(7):A146.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)01637-5/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)01637-5/pdf)
40. *Tatar M, Arsava M, Topçuoğlu M A, Çalışkan Z, Karabulut E, Tuna E, Şentürk A* (2016), 'Indirect Costs of Stroke in Turkey', Value in Health. 19(7): A648.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)33100-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)33100-X/pdf)
41. *Tatar M, Tuna E, Şentürk A, Sarıöz F, Konya A* (2016), 'Direct Costs of Chronic Obstructive Pulmonary Disease (COPD) in Turkey: A Panel Approach', Value in Health. 19(7): A552 [https://www.valueinhealthjournal.com/article/S1098-3015\(16\)32557-8/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)32557-8/pdf)
42. *Tatar M, Tuna E, Şentürk A, Sarıöz F, Konya A* (2016), 'Adherence to Gold Criteria Strategy in Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients: Cost Implications in Turkey', Value in Health. 19(7): A551.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)32548-7/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)32548-7/pdf)
43. *Tatar M, Şentürk A, Tuna E, Gurses C, Çağlayan GB, Firidin A* (2016), 'Indirect Costs of Epilepsy in Turkey: Cost of The Disease in Terms of Work Loss', Value in Health. 19(7): A430-A431. [https://www.valueinhealthjournal.com/article/S1098-3015\(16\)31855-1/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)31855-1/pdf)
44. *Tatar M, Şentürk A, Tuna E, Gurses C, Çağlayan GB, Firidin A* (2016), 'Direct Costs of Epilepsy in Turkey: A Panel Approach', Value in Health. 19(7): A431.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)31856-3/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)31856-3/pdf)
45. *Tatar M, Koçkaya G, Özelgün B, Elbir T, Şentürk A, Tuna E, Ünal S, Tümer A, İnkaya Ç* (2016), ' Indirect Cost of HIV/AIDS: Results of A Survey From A Turkish Research Center', Value in Health. 19(7): A411.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)31743-0/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)31743-0/pdf)
46. *Tatar M, Ünal S, Tümer A, İnkaya Ç, Koçkaya G, Şentürk A, Tuna E* (2016), 'Direct Cost of HIV/AIDS in Turkey', Value in Health. 19(7): A411-A412.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)31745-4/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)31745-4/pdf)
47. *Senturk A, Demir O, Tatar M, Ugurlu M, Sivaci C, Biter E, Kucuk I, Cankaya M, Colak E* (2016) 'Orphan Drug Market Analysis in Turkey', Value in Health. 19: A581.
[https://www.valueinhealthjournal.com/article/S1098-3015\(16\)32719-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(16)32719-X/pdf)
48. *Tatar M, Şentürk A, Tetik E, Yıldız L, Cheynel J* (2017), 'Budget impact of Alteplase in treatment of acute ischemic stroke in Turkey', Value in Health. 20(9): A607.
[https://www.valueinhealthjournal.com/article/S1098-3015\(17\)31517-6/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(17)31517-6/pdf)

49. *Tatar M, Şentürk A, Turgut GC, Doğan M, Türk FC* (2017), ‘Cost effectiveness of Contour curved cutter stapler in low anterior resection in Turkey’, *Value in Health*. 20(9):A596. [https://www.valueinhealthjournal.com/article/S1098-3015\(17\)31456-0/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(17)31456-0/pdf)
50. *Tatar M, Şentürk A, Nogueira E* (2017): ‘Cost effectiveness of DuraGraft as a vein graft treatment in coronary artery bypass grafting in Turkey’, *Value in Health*. 20(9): A587. [https://www.valueinhealthjournal.com/article/S1098-3015\(17\)31402-X/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(17)31402-X/pdf)
51. Şentürk A, *Tatar M* (2017), ‘Local production policies in the Turkish pharmaceutical market’, *Value in Health*. 20(9): A686. [https://www.valueinhealthjournal.com/article/S1098-3015\(17\)32068-5/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(17)32068-5/pdf)
52. *Tatar M, Şentürk A, Turgut CG, Tandoğan A, Bektaş T* (2017), ‘Cost effectiveness of bariatric surgery in Turkey: From a long-term perspective’, *Value in Health*. 20(9): A584. [https://www.valueinhealthjournal.com/article/S1098-3015\(17\)31385-2/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(17)31385-2/pdf)
53. *Tatar M, Tuna E, Şentürk A, Turgut CG, Erdoğan G, Sezginer G, Akkurt E* (2017), ‘Cost effectiveness of Pentaray high density mapping catheter in treatment of ventricular tachycardia in Turkey’, *Value in Health*. 20(9): A584. [https://www.valueinhealthjournal.com/article/S1098-3015\(17\)31388-8/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(17)31388-8/pdf)
54. *Tatar M, Senturk A, Turgut CG, Kocaman M* (2018), ‘Cost Effectiveness of Dermabond Prineo Skin Closure System in Hip and Knee Arthroplasty in Turkey’, *Value in Health*. 21: S253 [https://www.valueinhealthjournal.com/article/S1098-3015\(18\)34812-5/pdf](https://www.valueinhealthjournal.com/article/S1098-3015(18)34812-5/pdf)
55. *Tatar M, Özbalaş T, Yüzgenç C, Çilingiroğlu M, Tanrıseven R* (2022), ‘Cost-Effectiveness of Alpelisib Plus Fulvestrant for the Treatment of Postmenopausal Women with PIK3CA Mutant, HR+/HER2- Advanced Breast Cancer in Turkey’, *ISPOR Europe 2022 Konferansı*, 6-9 Kasım 2022, Viyana. <http://www.polarsaglik.com/uploads/polar/plr/Alpelisib-%20ISPOR-Europe%202022.pdf>
56. *Tatar M* (2022), ‘Cost-Effectiveness of Collagen Laminin-Based Dermal Matrix Combined with Resveratrol Microparticles in Treatment of Diabetic Foot Ulcer Treatment in Turkey’, *ISPOR Europe 2022 Konferansı*, 6-9 Kasım 2022, Viyana. <http://www.polarsaglik.com/uploads/polar/plr/Dermalix-%20ISPOR-Europe%202022.pdf>
57. *Ramirez DA, Tatar M, Alkış N, Güçlü ÇY, Bermede O, Erdemli B, Günaydın S* (2022), ‘Cost-effectiveness and budget impact analyses of implementing the first pillar of patient blood management, with intravenous (IV) ferric carboxymaltose (FCM), on the Turkish healthcare system’, *ISPOR Europe 2022 Konferansı*, 6-9 Kasım 2022, Viyana. <http://www.polarsaglik.com/uploads/polar/plr/Poster-ISPOR-EU-Cost-Effectiveness%20&%20Budget%20Impact%20of%20PBM%20in%20Turkey-4Oct-2022-v1.pdf>
58. *Tatar M* (2022), ‘Reimbursement of Pharmaceuticals in Turkey: Comparison with Approvals of the FDA between 2010-2021’, *ISPOR Europe 2022 Konferansı*, 6-9 Kasım 2022, Viyana. <https://vitalehealthconomics.co.uk/content/uploads/Market%20Access%20Turkey%20ISPOR%20Europe%20s2022.pdf>
59. *Tatar M* (2022), ‘Reimbursement of Antineoplastic and Immunomodulating Agents in Turkey: Comparison with Approvals of the FDA between 2010-2021’, *ISPOR Europe 2022 Konferansı*, 6-9 Kasım 2022, Viyana.

<https://vitalehealthconomics.co.uk/content/uploads/Market-%20Accesss%20Antineoplastics%20Turkey%20ISPOR%20Europe%202022.pdf>

60. *Tatar M, Özbalaş T, Saraçoğlu B, Ölmez C, Yarcı B, Akdemir A, Yılmaz C, Şen S* (2022), ‘Cost Effectiveness of Siponimod for Secondary Progressive Multiple Sclerosis in Turkey’, ISPOR Europe 2022 Konferansı, 6-9 Kasım 2022, Viyana.
<http://www.polarsaglik.com/uploads/polar/Siponimod%20Turkey%20ISPOR%20Europe%202022.pdf>
61. *Tatar M, Yarcı BŞ, Akdemir AC, İğde F, Tınaz E* (2023), ‘Cost-Effectiveness of Ofatumumab in Treatment of Relapsing Multiple Sclerosis in Türkiye’, ISPOR Europe 2023 Konferansı, 13-15 Kasım 2022, Kopenhag.
<https://www.polarsaglik.com/uploads/polar/Ofatumumab%20ISPOR%20Europe%202023.pdf>
62. *Tatar M, Çağlar P, Arbay D, Akdemir AC* (2023), ‘Cost-Effectiveness of Ribociclib plus a Non-Steroidal Aromatase Inhibitor for the Treatment of Pre- and Peri-Menopausal Women with HR+/HER2 Advanced Breast Cancer in Türkiye’, ISPOR Europe 2023 Konferansı, 13-15 Kasım 2022, Kopenhag.
<https://www.polarsaglik.com/uploads/polar/Valamor%20ISPOR%20Europe%202023.pdf>
63. *Tatar M, Ramirez De Arellano A, Akdeniz CS, Zeybey U, Şahin S, Çiftçi C* (2023), ‘Budget Impact of Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital, ISPOR Europe 2023 Konferansı, 13-15 Kasım 2022, Kopenhag.
https://vitalehealthconomics.co.uk/content/uploads/ISPOREurope23_Tatar_E11_POSTER_V2.pdf
64. *Sanal L, Günaydın S, Tatar M* (2023), ‘Cost Effectiveness and Budget Impact of Patient Blood Management in a Turkish State Hospital’, ISPOR Europe 2023 Konferansı, 13-15 Kasım 2022, Kopenhag.
https://vitalehealthconomics.co.uk/content/uploads/ISPOREurope23_Tatar_EE158_POSTER.pdf
65. *Tatar M, Kamacı, E, Alhagiri E, Alghamdi M* (2023), ‘Budget Impact of Efmoroctocog Alfa in Treatment of Severe Haemophilia A Patients in Turkey’, ISPOR Europe 2023 Konferansı, 13-15 Kasım 2022, Kopenhag.
https://vitalehealthconomics.co.uk/content/uploads/ISPOREurope23_TATAR_E417_POSTER.pdf
66. *Tatar M, Kamacı, E, Alhagiri E, Alghamdi M* (2023), ‘Cost-Effectiveness of Efmoroctocog Alfa in Treatment of Severe Haemophilia A Patients in Turkey’, ISPOR Europe 2023 Konferansı, 13-15 Kasım 2022, Kopenhag.
https://vitalehealthconomics.co.uk/content/uploads/ISPOREurope23_TATAR_E265_POSTER.pdf
67. *Tatar M, Kamacı, E, Alhagiri E, Alghamdi M* (2023), ‘Cost-Effectiveness of Eftrenonacog Alfa in Treatment of Severe Haemophilia B Patients in Turkey’ ISPOR Europe 2023 Konferansı, 13-15 Kasım 2022, Kopenhag.
https://vitalehealthconomics.co.uk/content/uploads/ISPOREurope23_TATAR_EE569_POSTER.pdf
68. *Tatar M, Kaplan BK, Arbay D, Akdemir AC* (2024), ‘Cost Effectiveness of Asciminib for the Post-2 Tyrosine Kinase Inhibitor Treatment of Chronic Myeloid Leukaemia in Türkiye, presented at ISPOR Europe 2024 Conference 17-21 Kasım, Barselona.
<https://polarsaglik.com/contents/yayinlarimiz/118>

69. Dane F, *Tatar M*, Göker E, Yıldız B, Sağlam S, Karaca M, Şeker M, Şendur M, Dilber F, Laçın Ş, Dulundu E, Köse F, Aydoğan D, Öztürk B, Yalçın Ş (2024), ‘Cost of Hepatocellular Carcinoma in Türkiye: Results of a Delphi Panel Analysis, presented at ISPOR Europe 2024 Conference 17-21 Kasım, Barselona. <https://polarsaglik.com/contents/yayinlarimiz/118>
70. Saydam G, Eşkazan AE, Güvenç B, Sönmez M, Toprak SK, *Tatar M*, Kaplan BK, Uçar B, Gür Ö, Haznedaroğlu İ (2024), ‘Cost of Chronic Myeloid Leukaemia in Türkiye: Results of a Delphi Panel Approach, presented at ISPOR Europe 2024 Conference 17-21 Kasım, Barselona. <https://polarsaglik.com/contents/yayinlarimiz/118>
71. Tatar M, Patron AP (2024), ‘Epidemiological Disparities and Risk Factors of Esophageal Cancer in Türkiye: A Systematic Review, presented at ISPOR Europe 2024 Conference 17-21 Kasım, Barselona. <https://polarsaglik.com/contents/yayinlarimiz/118>

Uluslararası Kitaplar

1. *Tatar M*, Mollahaliloğlu S, Şahin B, Aydın S, Maresso A, Hernández- Quevedo C (2011) Turkey: Health system review. Health Systems in Transition, European Health Observatory. 13(6):1–186.

Uluslararası Kitaplarda Bölüm

1. *Tatar M*, Mollahaliloğlu S (2015), in Maresso, A et al (eds), ‘Economic crisis health systems and health in Europe, Countries Experience (Turkey)’, WHO Regional Office for Europe, Kopenhag.

Uluslararası Raporlar

1. Berman P, *Tatar, M* (2003) ‘National Health Accounts Turkey 1999,2000’, Ministry of Health.
2. *Tatar M* (2007), ‘Pharmaprofile, Turkey’, Pharmaceutical Pricing and Reimbursement Project. www.ppri.oebig.at
3. Knapp M, McDaid D, Medeiros H, Becker T, Johnson J, Kilian R, Salvador-Carulla S, Simon J, *Tatar, M* (2008), ‘Economics, Mental Health and Policy: An Overview’, MHEEN II Policy Briefing No1. London.
4. Carter S, Taylor D, Kanavos P, Grimaccia F, Tordrup D, *Tatar M*, (2012), ‘Transforming Health in Turkey: 21st Century Opportunities’, UCL School of Pharmacy, London.
5. Lichtenberg F, *Tatar M*, Çalışkan Z (2014), ‘The Effects of Pharmaceutical Innovation on Longevity, Hospitalization and Health Expenditures in Turkey (1999-2010)’, Polar Health Economics and Policy, Ankara. www.polarhealth.com
6. *Tatar M* (2017), ‘Short Pharma Profile Turkey’, Pharmaceutical Pricing and Reimbursement Project. http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationReports/Short_PPRI_Pharma_Profile%20Turkey%202017_consolidated.pdf

Ulusal Dergilerde Yayınlanan Makaleler

1. *Tatar M* (1993), “Desantralizasyon ve Sağlık Reformları: Türk Sağlık Sisteminde Yeni Yapılanma Modeline Teorik bir Bakış”, *Amme İdaresi*. 26(4).
2. *Tatar, M* (1993), “Teorik Boyutlarıyla Genel Sağlık Sigortası ve Türk Sağlık Yöneticilerine Öneriler”, Doğan, M. et al. (eds), *I. Ulusal Sağlık Kurumları ve Hastaneler Sempozyumu*, Dokuz Eylül Üniversitesi, İzmir.
3. *Tatar M* (1994), “Sağlık Hizmetlerinde Ekonomik Değerlendirme Yöntemleri”, *Verimlilik Dergisi*, 4.
4. *Tatar M* (1994), “Temel Sağlık Hizmetlerinin Tanımı ve Uygulamalarına Teorik bir Bakış”, *Toplum ve Hekim*. 9(60).
5. *Tatar M* (1994), “Temel Sağlık Hizmetlerinin Tanımı ve Uygulamalarına Teorik bir Bakış: Karmaşa mı Yanılgı mı?”, *Toplum ve Hekim*. 9(62).
6. *Tatar M* (1994), “Sigara: Devlet Politikaları Kullanımı Etkileyebilir mi?”, *Toplum ve Hekim*, 9(63).
7. *Tatar M* (1995), “Temel Sağlık Hizmetleri: Politik ve İdeolojik bir Yaklaşım”, *Toplum ve Hekim*. 10(67).
8. *Tatar M* (1995), “Temel Sağlık Hizmetleri Yaklaşımının Vazgeçilmez Ögesi: Toplum Katılımı”, *Toplum ve Hekim*. 10(67).
9. *Tatar F, Tatar M, ve diğerleri* (1995), “Hastane Yönetiminde Gelecekte Önem Kazanacak Alan ve Konular ile Bu Konularda Başarılı Olmak için Gerekli Bilgi, Beceri ve Yetenekler”, *Toplum ve Hekim*. 10(69-70).
10. *Tatar M* (1996), “Polio Aşı Kampanyasının Düşündürdükleri: Kampanyalar Sağlık Sorunlarına Çözüm mü yoksa Tehdit mi?”, *Toplum ve Hekim*. 11(71).
11. *Tatar F, Tatar M* (1996), “Sağlık Hizmetlerinde Özel Sektör/Kamu Sektörü Tartışmasının İdeolojik Boyutu”, *Toplum ve Hekim*. 11(72).
12. *Tatar M, Tatar F* (1996), “Sağlığın Ölçülmesi: Kavramsal bir Çerçeve”, *Toplum ve Hekim*. 11(73).
13. *Tatar F, Tatar M, Şahin I* (1997), “Hastane Hizmet İhaleleri: Teori ve Türkiye’deki Uygulamalar”, *Amme İdaresi Dergisi*. 30(3).
14. *Tiryaki D, Tatar M* (2000), “Sağlık Sigortası: Teori ve Uygulama”, *Hacettepe Sağlık İdaresi Dergisi*. 5(4):124-138.
15. *İşnas C, Tatar M* (2000), “Doktor-Hasta İlişkisi: Ankara Numune Hastanesi Ortopedi Kliniklerinde Yatan Hastaların Değerlendirmeleri”, *Hacettepe Sağlık İdaresi Dergisi*. 5(3): 147-159.
16. *Ağırbaş İ, Tatar M* (2001), “Sağlık Hizmetlerinde Ekonomik Değerlendirme: Bir Maliyet Etkililik Analizi Uygulama Örneği”, *Verimlilik Dergisi*. 1:139-152.
17. *Tatar M* (2001), “Sağlık Hizmeti Sunan Profesyonellere Ödeme Yöntemleri”, *Sağlık ve Toplum*. 11(4).
18. *Tatar M, Şahin İ, Büyükkayıkçı H* (2004), “Sağlık Hizmetlerinde Öncelik Belirleme: Teori ve SSK Hastaneleri Yöneticilerinin Görüşleri”, *Hacettepe Sağlık İdaresi Dergisi*. 2004..
19. *Özgen H, Tatar M* (2007), “Sağlık Sektöründe bir Verimlilik Değerlendirme Tekniği Olarak Maliyet-Etkililik Analizi ve Türkiye’de Durum”, *Hacettepe Sağlık İdaresi Dergisi*.
20. *Özgen H, Tatar M* (2008), “Sağlık Hizmetleri Finansmanında İnfomal Ödemeler”, *Hacettepe Sağlık İdaresi Dergisi*, 11(1).
21. *Tatar M* (2011), ‘Sağlık Hizmetlerinin Finansman Modelleri: Sosyal Sağlık Sigortasının Türkiye’de Gelişimi ve Gelecek’, *Sosyal Güvenlik Dergisi*, 1(1).

Ulusal Kitaplar

1. *Tatar M, Tatar F (1998), Birinci Basamak Sağlık Hizmetlerinde Maliyet Analizi, Creese A.; Parker, D. (eds), Cost Analysis in Primary Health Care Translation to Turkish, Ministry of Health Project Coordination Unit, Ankara.*
2. *Tatar M, Tatar F (1998), Yerel Yönetimler ve Sağlık, Konrad Adenauer Vakfı ve Türk Belediyeler Birliği, Ankara.*
3. *Tatar M (2000), Sağlık Hesapları Sistemi (A System of Health Accounts) Türkçe'ye çeviri, OECD.*
4. *Tatar M, Wertheimer A (2010), Sağlık Teknolojilerinin Değerlendirilmesi. İlaç Geri Ödeme Kararları için bir Model Önerisi, SUVAK, Ankara.*
5. *Tatar M (2012), (ed.), Sağlık Kurumları Yönetimi I, Anadolu Üniversitesi Yayınları No 2631, Eskişehir.*
6. *Koçkaya G, Tatar M, (Çeviri Editörleri) (2013), Tıbbi Cihazlarda Sağlık Teknolojisi Değerlendirmesi. DSÖ Tıbbi Cihaz Teknik Serisi, (WHO- Health Technology Assessment of Medical Devices kitabının çevirisi), Sağlık Ekonomisi ve Politikası Derneği, Ankara. <http://sepd.org.tr/wp-content/uploads/2017/08/Tibbicihazlardasaglikteknolojidegerlendirmesi.pdf>*

Ulusal Kitaplarda Bölüm

1. *Tatar M (2003), “Sağlık Politikası” içinde Göksu, T. ve diğerleri, **1980-2003 Türkiye'nin Dış Ekonomik, Sosyal ve İdari Politikaları**, Siyasal Kitabevi, Ankara.*
2. *Tatar M (2007), “Sağlık Politikası Ve Politika Belirleme Süreci : Teori Ve Türk Sağlık Politikalarına Genel Bir Bakış”, içinde Aktan, C.C. ve Saran U. (eds), Sağlık Ekonomisi ve Sağlık Yönetimi, Sağlıkta Umut Vakfı, Ankara.*
3. *Tatar M (2007), “Sağlık Sisteminin Performansını Ölçme Süreci”, içinde Ateş, H ve diğerleri, Sağlık Sektöründe Performans Yönetimi, Asil yayın Dağıtım Ltd. Şti.*
4. *Tatar M, Şahin I (2007), “Türkiye’de Kanser Harcamaları”, Tuncer, M. (ed), Türkiye’de Kanser Kontrolü, Sağlık Bakanlığı, Ankara.*
5. *Tatar M (2007), “Türkiye’de Sağlık Reformları ve Hasta Açısından Yeni Sistemin Getirdikleri”, Babaoğul, M.; Şener, A., (eds), Tüketici Yazıları I, Hacettepe Üniversitesi Tüketici Pazar Araştırma Danışma Test ve Eğitim Merkezi.*
6. *Tatar M (2013), ‘Sağlık Ekonomisi’, Sur, H.; Palteki, T., (eds), Hastane Yönetimi, Nobel Tıp Kitapevleri.*

Web Yayınları

1. *Tatar M (2017), ‘İlaçta fiyatlandırma ve geri ödeme politikalarında değer kavramı’ (Pricing of pharmaceuticals and the concept of value in reimbursement policies), Polar Health Economics and Policy Consultancy, Health Economics and Policy Studies 1, <http://polarsaglik.com/contents/yayinlarimiz/263>*
2. *Tatar M (2017), ‘Gen tedavileri ve geri ödeme kurumlarının yeni sınavı’ (Gene therapy and new challenges for reimbursement agencies), Polar Health Economics and Policy*

- Consultancy, Health Economics and Policy Studies- 2, <http://polarsaglik.com/uploads/polar/makale/Gen-tedavileri.pdf>
3. *Tatar M* (2017) ‘Geri Ödemede eşik değeri: Teori ve uygulama’, (Threshold value in Reimbursement: Theory and practice), Health Economics and Policy Studies – 3,
 4. *Tatar M* (2019) ‘HIV/AIDS in Turkey, Health Economics and Policy Studies – 4, <http://polarsaglik.com/uploads/polar/Polar-HIV-Report.pdf>
 5. *Tatar M* (2018), ‘Reimbursement of Pharmaceuticals in Turkey: Are We Aware of the Approaching Threat’, <https://vitalehealthconomics.co.uk/content/uploads/Reimbursement-of-drugs-in-Turkey-2018.pdf>
 6. *Tatar M* (2019), ‘Reimbursement of Pharmaceuticals in Turkey: 2019’, <https://vitalehealthconomics.co.uk/content/uploads/Reimbursement-of-drugs-in-Turkey-2019.pdf>
 7. *Tatar M* (2020), ‘Reimbursement of Pharmaceuticals in Turkey: 2019’, <https://vitalehealthconomics.co.uk/content/uploads/Reimbursement-of-drugs-in-Turkey-2020.pdf>
 8. *Tatar M* (2021), ‘Access to Innovative Medicines in Turkey: The Impact of Rigorous Pricing and Reimbursement Policies’, Vitale Policy Studies 1, <https://vitalehealthconomics.co.uk/content/uploads/Access%20to%20medicines%20in%20Turkey-2021.pdf>

Blog Yazıları

1. *Tatar M* (2018), ‘What do the new high-level economic policy documents tell for the health sector in Turkey’, <https://wordpress.com/read/feeds/80040853/posts/2055781687>
2. *Tatar M* (2018), ‘The 2019 budget presentation of the Minister of Health: What does it say for our health care system’, <https://wordpress.com/read/feeds/80040853/posts/2108348767>
3. *Tatar M* (2018), ‘City Hospitals of Turkey’, <https://health-in-turkey.com/2018/06/04/city-hospitals-of-turkey/>
4. *Tatar M* (2018), ‘Health Technology Assessment in Turkey’, <https://health-in-turkey.com/2018/04/29/health-technology-assessment-in-turkey/>
5. *Tatar M* (2019) ‘Reimbursement of pharmaceuticals in Turkey: Are we aware of the approaching threat’, <https://wordpress.com/read/feeds/80040853/posts/2154389403>
6. *Tatar M* (2019), ‘Emerging expensive technologies and the Turkish reimbursement system: Time for revision?’, <https://wordpress.com/read/feeds/80040853/posts/2387126131>
7. *Tatar M* (2019), ‘Reimbursement by Court Decisions: How Should the Social Security Institution Respond?’, <https://health-in-turkey.com/2019/12/11/reimbursement-by-court-decisions-how-should-the-social-security-institution-respond/>
8. *Tatar M* (2019) ‘Health Expenditures in Turkey: Hidden Facts Behind Figures’, <https://health-in-turkey.com/2019/11/18/health-expenditures-in-turkey-hidden-facts-behind-figures>
9. *Tatar M* (2020), ‘Reimbursement of Pharmaceuticals in Turkey: 2019’, <https://health-in-turkey.com/2020/02/10/reimbursement-of-pharmaceuticals-in-turkey-2019/>
10. *Tatar M* (2017), ‘Sağlık hizmetlerinde değeri kavramı’, <https://wordpress.com/read/feeds/73366432/posts/1637408397>
11. *Tatar M* (2017), ‘Gen tedavileri ve geri ödeme kurumlarının yeni sınavı’, <https://mehtaptatarsaglikekonomisi.wordpress.com>

12. *Tatar M* (2018), ‘Geri ödemedeki eşik değeri ne olmalı?’, <https://wordpress.com/view/mehtaptatarsaglikekonomisi.com>
13. *Tatar M* (2018), ‘Sağlık hizmetlerinde değer bazlı ödeme yöntemi: Sağlık politikaları kavramlar çöplüğünün yeni adayı mı?’, <https://wordpress.com/view/mehtaptatarsaglikekonomisi.com>
14. *Tatar M* (2018), ‘Yapay zeka ve sağlık hizmetleri: Sağlık hizmetleri politikalarında değişimin bir başka habercisi mi?’, <https://wordpress.com/view/mehtaptatarsaglikekonomisi.com>
15. *Tatar M* (2018), ‘Sağlık hizmetlerinde değer bazlı ödeme: Nasıl bir örgütlenme? 1,2,3’, <https://wordpress.com/view/mehtaptatarsaglikekonomisi.com>
16. *Tatar M* (2019), ‘Trump yönetiminin yeni ilaç fiyatlandırma politikası: Çözüm ABD’de mi yoksa diğer ülkelerde mi?’, <https://wordpress.com/view/mehtaptatarsaglikekonomisi.com>
17. *Tatar M* (2019), ‘Modern tıbbın yeni teknolojilerle sınavı: CRISPR tekniği/ Türkiye sağlık yatırımlarında doğru yerde mi?’, <https://wordpress.com/view/mehtaptatarsaglikekonomisi.com>
18. *Tatar M* (2019) ‘Spinal Müsküler Atrofi (SMA) gen tedavisinin onayı: Sağlık yatırımlarımızı sorgulamamız için yeni bir işaret mi?’, <https://wordpress.com/view/mehtaptatarsaglikekonomisi.com>
19. *Tatar M* (2020), ‘COVID-19 Salgını: Sağlık Politikalarında değişimin ayak sesleri?’, <https://mehtaptatarsaglikekonomisi.com/2020/06/03/covid-19-salgini-saglik-politikalarinda-degisimin-ayak-sesleri/>
20. *Tatar M* (2020), ‘Türkiye’nin Covid 19 Verileri: Veri Paylaş(a)mama Kültürümüzün Yeni Bir Örneği mi?’, <https://mehtaptatarsaglikekonomisi.com/2020/08/11/turkiyenin-covid-19-verileri-veri-paylasamama-kulturumuzun-yeni-bir-ornegi-mi/>

BİLİMSEL TOPLANTILAR

Uluslararası Bilimsel Toplantılar

1. *Tatar M* (1992), “Turkish National Health Policy Paper: A Reflection of European Policies?” British Sociology Group Conference, paper presented at the joint conference with the European Society of Medical Sociology, 18-21 September, 1992, Edinburgh.
2. *Tatar M* (1992), “Is Health for Achievable?: The Case of Turkey”, paper presented at the Twelfth International Conference on the Social Sciences and Medicine, 14-18 September, 1992, Peebles, Scotland.
3. Akbulut Y, *Tatar M* (2004), “Standardized Mortality Ratios and Allocation of Health Care Resources. Turkey Case” paper presented at the Third International Conference on Health Economics, Management and Policy, June 3-5, 2004, Athens, Greece.
4. Akbulut Y, Demir A, *Tatar M* (2004), “Allocation of Health Care Resources: An Attempt to Develop a Need Index for Turkey” paper presented at the Fifth European Conference on Health Economics, 8-11 September, 2004, London, England
5. *Tatar M* (2004), “Health System Financing in Azerbaijan; equity in access to care” Conference on Reforming the Health Sector in Azerbaijan, Azerbaijan Ministry of Health and the World Bank, 1-3 December 2004, Baku.
6. *Tatar M* (2005), “Health and Pharmaceutical Expenditures and Pharmacoeconomics in Turkey” I. International Health and Pharmacoeconomics Symposium, 24-25 May 2005, Ankara

7. Akbulut Y, *Tatar M* (2005), “Health Planning and Epidemiologic Measures: An Evaluation of Turkey’s Mortality and Mortality Data” IFSSH World Congress, 21-26 August 2005, İstanbul
8. *Tatar M* (2006), “Health Technology Assessment in Turkey” European Advisory Second Group meeting on Health and Social Policies, London School of Economics 9 June 2006.
9. *Tatar M* (2006), “The State of Oncology in Turkey” European Advisory Second Group meeting on Health and Social Policies, London School of Economics, London, 15 December 2006.
10. *Tatar M* (2007), “Türkiye’de Kanser Harcamaları ve Farmakoekonomi” (Cancer Expenditures in Turkey and Pharmacoeconomics) Etkin Kanser Kontrol Programları Türkiye ve KKTC’de Kanser Kontrolü Sempozyumu, North Cyprus Turkish Republic February, 2007.
11. *Tatar M* (2007), “Challenges in developing mental health policy and practice in Turkey”, Mental Health in Europe: Recent Findings and Analysis from the Mental Health Economics European Network Phase II, London School of Economics, London 27 September 2007.
12. *Tatar M* (2007), “Oncology in Turkey” European Advisory Second Meeting on Health and Social Policies, Fifth Meeting, 6-8 December, 2007.
13. *Tatar M* (2009), “Cost effectiveness of Sorafenib in unresectable and/or metastatic renal cell carcinoma in Turkey” Podium presentation in ISPOR 12th Annual European Congress, 24-27 October 2009, Paris.
14. *Tatar M* (2010), “Health care resources and their rational use: Health technology assessment and national health expenditures”, TUBITAK-Academy of Finland, Public Health Workshop 4-5 May, 2010 İstanbul.
15. Somunoğlu S, *Tatar M* (2010), “Breast Cancer Policies and Practices in the World and in Turkey”, Sixth International Conference on Health Care Systems, Zirve University and University of Houston Clear Lake, Gaziantep, 2010.
16. *Tatar M* (2011), ‘Health Care Reforms and Pharmaceuticals: Lessons From Turkey’, ICIUM 2011, Antalya.
17. *Tatar M* (2011), ‘Financing, Service Provision, Institutional Arrangements and Governance Options in Developing Countries: Lessons from Turkey’, National Health Insurance: Lessons for South Africa Conference, South Africa, 7-8 December, Protea.
18. *Tatar M* (2013), ‘Reimbursement of pharmaceuticals in Turkey’, Future Trends Workshop, Dubai, 12-14 April.
19. *Tatar M* (2013)i ‘Pricing and reimbursement of pharmaceuticals in Turkey’ Russian Pharmaceutical Forum, St. Petersburg, 21-23 May.
20. *Tatar M* (2013), ‘Hospital based payment plan- The Turkish benchmark’, Hospital Build and Infrastructure Middle East, Dubai, 3-5 June.
21. *Tatar M* (2013), ‘Cost of obesity and economic value of obesity surgery for Turkey’, 18th World Congress of International Federation for Surgery of Obesity and Metabolic Disorders, 28-31 August 2013, İstanbul.
22. *Tatar M* (2013), ‘Integration: The story from the health economics and health policy perspective with examples from Turkey and Europe’, European Forum for Primary Health Care Conference, 9-10 September, 2013 İstanbul.
23. *Tatar M* (2014), ‘The impact of pharmaceutical reimbursement decisions on health indicators and healthcare services: Examples from Turkey and abroad’, 17th International Pharmaceutical Technology Symposium, September, 8-10, 2014, Antalya.
24. *Tatar M* (2014), ‘Assessment of the Turkish health care system trends from a health economics perspective: Insights from Turkish health care system’, 3rd Middle East Future Trends Forum, 28-29 November 2014, Dubai.

Ulusal Bilimsel Toplantılar

1. Tiryaki D, *Tatar M* (1999), “Özel Sağlık Sigortası Yaptırma Nedenleri ve Sigortadan Duyulan Tatmin Düzeyi”, II. Ulusal Sağlık Kurumları ve Hastane Yönetimi Sempozyumu, 15-16 Mayıs 1999.
2. İşnas C, *Tatar M* (1999), “Doktor Hasta İlişkisi”, II. Ulusal Sağlık Kurumları ve Hastane Yönetimi Sempozyumu, 15-16 Mayıs 1999.
3. *Tatar M*, Çelik Y, Şahin İ (2000), “Hastane Yönetiminde Gelecekte Önem Kazanacak Konular ve Gerekli Bilgi, Beceri ve Yetenekler”, I. Ulusal Sağlık İdaresi Kongresi, 20-21 Mayıs 2000.
4. Ağırbaş İ, *Tatar M* (2000), “Sağlık Hizmetlerinde Ekonomik Değerlendirme Teknikleri”, I. Ulusal Sağlık İdaresi Kongresi, 20-21 Mayıs 2000.
5. *Tatar M* (2002), “Geriatri Merkezlerinin Organizasyonu **Geriatri 2000**, 1-2 Nisan 2002
6. Şahin B, *Tatar M*, Karakaya G, Kalyoncu F (2003), “Asthma Quality Of Life Questionnaire’ın Türkçe Uyarlamasının Geçerlik ve Güvenirliği” Altıncı Torax Derneği Kongresi, Mayıs 2003, Antalya, Turkey.
7. Şahin B, *Tatar M*, Karakaya G, Kalyoncu F, Artvinli M (2003), “Özel Poliklinik Uygulamasının Astım Hastalarının Tedavi Giderleri ve Tatmin Düzeyleri Üzerine Etkisi”, Altıncı Torax Derneği Kongresi, Mayıs 2003, Antalya
8. *Tatar M* (2005), “Türkiye’de Sağlık Harcamaları, İlaç Harcamaları ve Farmakoekonomi”, 1. Uluslararası Sağlık Ekonomisi ve Farmakoekonomi Sempozyumu”, Mayıs 2005, Ankara.
9. *Tatar M* (2005), “USH veri Toplama Kaynakları ve Stratejileri”, Sağlık Bakanlığı, Ulusal Sağlık Hesapları Çalıştayı, Ekim, 2005.
10. *Tatar M* (2005), “Türkiye’de Sağlık Sorunları ve Çözüm Önerileri”, Gülhane Askeri Tıp Akademisi, Kasım 2005.
11. *Tatar M* (2006), “Ulusal Sağlık Hesapları”, Basın Mensupları için Araştırmacı İlaç Firmaları tarafından düzenlenen toplantı, 15 Nisan, 2006, İstanbul.
12. *Tatar M* (2006), “Sağlıkta Ekonomik Değerlendirme Teknikleri ve Farmakoekonomi”, Basın Mensupları için Araştırmacı İlaç Firmaları tarafından düzenlenen toplantı, 15 Nisan, 2006, İstanbul.
13. *Tatar M* (2006), “Türkiye’de Sağlık Ekonomisi ve İlaç” Sağlık ve İlaç Ekonomisinde Eğilimler. Dünya ve Türkiye’deki Gelişmeler, Araştırmacı İlaç Firmaları Derneği 31 Mayıs 2006
14. *Tatar M* (2006), “Türkiye’de Sağlık harcamaları ve Sağlık Hizmetlerinin Finansmanı” Türk Silahlı Kuvvetleri 15. Tıp Kongresi 31 Mayıs 2006.
15. *Tatar M* (2007), “Sağlık Ekonomisi” TEB Akademi, Türkiye Eczacılar Birliği, Nisan, 2007
16. *Tatar M* (2009), “Geri ödeme sistemleri: Avrupa’dan örnekler“, Farmavizyon Eczacılık Fuarı 10-12 Nisan 2009 İstanbul.
17. *Tatar M* (2009), “Sosyal Güvenlik Kurumunun Özel Sektör ile Etkili İşbirliği İçin Model Önerisi”, Özel Sağlık Kuruluşlarının Sorunları Sempozyumu 17 Nisan Bilkent Otel, Ankara.
18. *Tatar M* (2009), “Transfüzyonel hemosideroz tedavisinde kullanılan şelatörlerin etkilik ve maliyet değerlendirmesi”, Talasemi Tedavisinde Multidisipliner Yaklaşımlar Çalıştayı, Antalya.
19. *Tatar M* (2010), “IMF, Dünya Bankası ve Sağlık Politikaları”, 1. Sağlık Kurumları İşletmeciliği ve Gelişen Tıp Teknolojileri Kongresi, Antalya.
20. *Tatar M* (2010), “Sağlık Teknolojilerinde Yaşam Kalitesi Analizlerinin Rolü”, 3. Ulusal Sağlıkta Yaşam Kalitesi Kongresi, İzmir

21. *Tatar M* (2010), “Farmakoekonomi ve Türkiye’de Uygulanabilirliđi”, Third International Meeting on Pharmacy and Pharmaceutical Sciences, 9 Haziran 2010, İstanbul.
22. *Tatar M* (2011), ‘Farmakoekonomi’, 4th Ulusal Osteoporoz Kongresi, Antalya.
23. Ergin G, *Tatar M* (2012), ‘Diyaliz Seans Maliyetlerinin Belirlenmesi: Özel Diyaliz Merkezleri Örneđi’, 1. Sağlık Ekonomisi Kongresi, Sağlık Ekonomisi ve Politikası Derneđi, 22-24 Kasım 2012, Ankara.
24. *Tatar M* (2014), ‘Sađlık Ekonomisi ve Sađlık Politikaları Perspektifinden Türkiye ve Avrupa Entegrasyonu’, 13. Uluslararası Dođu Akdeniz Aile Hekimliđi Sempozyumu, 23-25 Mayıs 2014, Adana.
25. *Tatar M* (2016) ‘Epilepsi Yüğü’, 10. Ulusal Epilepsi Kongresi, 12-15 Mayıs 2016, İzmir.
26. *Tatar M* (2016), ‘Eczacılıkta Yenilik ve Sađlık Çıktıları: Türkiye Örneđi’ Sađlık Politikaları Çalıştayı, TOBB- ABD Ticaret Odası, 20 Nisan 2016, Ankara.